HMPL-689

DRUG5 trials

Sponsors

Hutchison Medipharma Limited, Hutchmed

Conditions

Follicular LymphomaHealthy VolunteersLymphomaLymphomasMarginal Zone LymphomaRelapsed/Refractory Lymphoma

Phase 1

A Study of HMPL-689 in Healthy Volunteers

CompletedNCT02631642

Hutchison Medipharma LimitedHealthy Volunteers

Start: 2016-03-23End: 2017-02-28Updated: 2017-08-17

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

CompletedNCT03128164

Hutchison Medipharma LimitedLymphomas

Start: 2017-08-08End: 2023-08-02Updated: 2023-08-23

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

TerminatedNCT03786926

HutchmedLymphoma

Start: 2019-08-26End: 2024-06-26Updated: 2025-06-26

Phase 2

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

CompletedNCT04849351

Hutchison Medipharma LimitedFollicular Lymphoma, Marginal Zone Lymphoma

Start: 2021-04-15End: 2024-02-29Updated: 2025-04-06

A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma

CompletedNCT05713110

HutchmedRelapsed/Refractory Lymphoma

Start: 2023-02-13End: 2024-12-31Updated: 2025-01-22

Related Papers

UPDATED RESULTS FROM A PHASE 1B STUDY OF AMDIZALISIB, A NOVEL INHIBITOR OF PHOSPHOINOSITIDE 3‐KINASE‐DELTA (PI3Kδ), IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA

Hematological Oncology2023-06-012 citations

Abstract 5454: Amdizalisib (HMPL-689), a highly selective PI3Kδ inhibitor, exhibits potent anti-tumor activity in pre-clinical B-cell lymphoma models

Cancer Research2022-06-153 citations

A Phase 1 Study of HMPL-689, a Small Molecule, Highly Selective, and Potent Inhibitor of Phosphoinositide 3 Kinase-Delta, in Patients with Relapsed or Refractory Lymphoma

Blood2020-11-043 citations

Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Blood2020-11-042 citations